Covered recipient · General Payments record
TIMOTHY M KITCHEN
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$2,211.39
- Reported across 59 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $348.49 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $84.73 | 4 |
| Lilly USA, LLC | $63.45 | 3 |
| Merck Sharp & Dohme Corporation | $47.13 | 2 |
| PFIZER INC. | $39.42 | 2 |
| BioMarin Pharmaceutical Inc. | $27.73 | 1 |
| Exact Sciences Corporation | $26.94 | 1 |
| ABBVIE INC. | $22.15 | 1 |
| Astellas Pharma US Inc | $20.67 | 1 |
| Acerta Pharma LLC | $16.27 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $22.15 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104082000 | CMS |
| Astellas Pharma US Inc | $20.67 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139276062 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.27 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105848131 | CMS |
| BioMarin Pharmaceutical Inc. | $27.73 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1127060625 | CMS |
| Exact Sciences Corporation | $26.94 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114737211 | CMS |
| Lilly USA, LLC | $16.43 | 02/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135450354 | CMS |
| Lilly USA, LLC | $24.67 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135467733 | CMS |
| Lilly USA, LLC | $22.35 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135465986 | CMS |
| Merck Sharp & Dohme LLC | $26.93 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141938875 | CMS |
| Merck Sharp & Dohme LLC | $20.20 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141883927 | CMS |
| Novo Nordisk Inc | $14.54 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097165349 | CMS |
| Novo Nordisk Inc | $21.50 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097071925 | CMS |
| Novo Nordisk Inc | $29.43 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097255858 | CMS |
| Novo Nordisk Inc | $19.26 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097433710 | CMS |
| PFIZER INC. | $21.40 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130998624 | CMS |
| PFIZER INC. | $18.02 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131397493 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.